Decision of the Complaints Committee – 04932-21 Various v
Daily Express
Summary of Complaint
1. The Independent Press Standards Organisation received
various complaints that the Daily Express breached Clause 1 (Accuracy) of the
Editors’ Code of Practice in an article headlined “UK gets new lung cancer
drug...thanks to Brexit deal”, published on 7 May 2021.
2. The article reported that the UK had authorised a “new
lung cancer drug” under an international scheme that the country was “able to
join after Brexit” having signed up to the US-led Project Orbis in January
2021. It reported that the drug – called Osimertinib – was made by AstraZeneca
and sold under the brand name Tagrisso. It stated that this medication was
taken in tablet form and “originally licensed to treat patients with mid and
later stage non-small cell lung cancer who carry a gene mutation called EGFR”
but has since “been extended to include those in early-stage disease after the
cancer is surgically removed.” The article went on to include the comments made
by the Health Secretary, Matt Hancock MP, who said that “leaving the European
Union (EU) had presented [the country] with the opportunity to join Project
Orbis - a collaboration with the top regulators around the world – to speed up
the time it takes to get new medicines to patients”, adding that he was
delighted to see the “first results” of this undertaking. He said that the “ground-breaking drug for
lung cancer” would soon benefit hundreds of patients across the UK.
3. A substantially similar version of the article also
appeared online under the headline “UK gets new lung cancer drug under
international scheme thanks to Brexit deal”.
4. IPSO received 34 complaints about this article.
Complainants said the headline was inaccurate and misleading on two points.
First, to report that there was a “new lung cancer drug” given that the
medication ‘Tagrisso’ was already licensed and available to EU countries,
including the UK, following its approval by the European Medicines Agency (EMA)
in 2016. Second, to report that “thanks to Brexit” the UK was able to authorise
this “new drug”, given that it had been available for use since 2016.
5. The newspaper did not accept a breach of the Editors’
Code on either point. The newspaper accepted that the drug ‘Tagrisso’ had
originally been licensed in the UK to treat patients with mild and later stage
non-small lung cancer. However, it said that the recent authorisation had
allowed a new use of the medication, earlier in the disease, that extended its
use to a further cohort of patients, who were previously ineligible. It said that this was made clear in the body
of the article, which said the drug had been “originally licensed to treat
patients with mid and later stage non-small cell lung cancer who carry a gene
mutation called EGFR” but has since “been extended to include those in early-stage
disease after the cancer is surgically removed.” In such circumstances, the
newspaper said the headline was not significantly misleading to describe the
medication as “a new cancer drug”.
6. In regard to the second point of complaint, the newspaper
said the article was based upon a press release issued by the UK’s Medicines
and Healthcare products Regulatory Agency (MHRA). This included the statement
made by the Health Secretary, Matt Hancock MP, who said that “leaving the EU
[had] presented [the UK] with the opportunity to join Project Orbis” and
authorise the “ground-breaking drug”.
Relevant Code Provisions
Clause 1 (Accuracy)
i) The Press must take care not to publish inaccurate,
misleading or distorted information or images, including headlines not
supported by the text.
ii) A significant inaccuracy, misleading statement or
distortion must be corrected, promptly and with due prominence, and — where
appropriate — an apology published. In cases involving IPSO, due prominence
should be as required by the regulator.
iii) A fair opportunity to reply to significant inaccuracies
should be given, when reasonably called for.
iv) The Press, while free to editorialise and campaign, must
distinguish clearly between comment, conjecture and fact.
Findings of the Committee
7. In considering the care taken by the newspaper, the
Committee had regard to the context of the article. The Committee noted that
the article reported on an announcement by the MHRA and the then Health
Secretary, Matt Hancock MP, with the latter describing the authorisation of the
drug ‘Osimertinib’ in the context of “new medicines” being brought to the UK
market after Brexit. In addition, the Committee noted that the article had made
clear the basis for the claim, specifically that the drug had been approved for
a new usage. On this basis, the Committee concluded that there was no failure
to take care over the accuracy of the article in breach of Clause 1 (i).
8. The Committee next considered whether the article
contained significant inaccuracies or was significantly misleading. It was not
in dispute that, as explained in the text of the article, the drug had been
authorised for use in a new way to treat cancer, and would therefore be
available to a new set of patients. In addition, the body of the article made
clear that, according to the former Health Secretary, the UK’s departure from
the EU had afforded it the opportunity to join Project Orbis, which had been
responsible for approving the use of the drug for this new treatment of cancer
patients – a treatment which had not yet been approved by the EU regulator. In
such circumstances, and taking into account the above, the Committee did not
consider the article significantly inaccurate or misleading as to require
correction under Clause 1 (ii). There was no breach of Clause 1.
Conclusion
9. The complaint was not upheld.
Remedial Action Required
10. N/A
Date complaint received: 7/05/2021
Date complaint concluded by IPSO: 27/08/2021
Back to ruling listing